Anlotinib Combined With Docetaxel Versus Docetaxel for Previous Treated Advanced NSCLC

NCT03726736 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

97

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Anlotinib combined Docetaxel
DRUG: Docetaxel

Sponsor

Yong Fang

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]